"Moderna's Next-Generation COVID-19 Vaccine Outperforms Current Shot in Phase 3 Trial"
Moderna has reported positive interim results from the Phase 3 trial of its next-generation COVID-19 vaccine, mRNA-1283, showing a stronger immune response compared to its licensed COVID-19 vaccine, mRNA-1273.222. The new vaccine design offers potential storage advantages and paves the way for a combination vaccine against influenza and COVID-19. The trial demonstrated a higher immune response against both Omicron and original virus strains, particularly in participants over 65 years old. The vaccine's safety profile was found to be similar to Moderna's approved COVID-19 vaccines, and detailed trial data will be presented at upcoming events.